Viewing data from:

MYORISAN

ANDA

ISOTRETINOIN | A076485 | UPSHER SMITH LABORATORIES LLC

4 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Myorisan (2023)

Total Spending

$112K

Total Claims

465

Beneficiaries

303

Avg Cost/Unit

$5.61

Spending Trend

$1.3M(2019)→$529K(2020)→$476K(2021)→$391K(2022)→$112K(2023)

YoY Change:+6.8%

5yr CAGR:-1.3%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain8 active DMFs2 inactive

7 active API suppliers hold Drug Master Files for this ingredient.

OLON SPAISOTRETINOIN

DMF 74851988

JIANGXI HENGXIANG PHARMCEUTICAL TECHNOLOGY CO LTDISOTRETINOIN (NON-STERILE BULK FORM)

DMF 191912005

HAS HEALTHCARE ADVANCED SYNTHESIS SAISOTRETINOIN

DMF 199182006

CHONGQING HUAPONT PHARMACEUTICAL CO LTDISOTRETINOIN

DMF 216532008

BIOPHORE INDIA PHARMACEUTICALS PVT LTDISOTRETINOIN

DMF 274842013

SUN PHARMACEUTICAL INDUSTRIES LTDISOTRETINOIN USP

DMF 325172018

CHONGQING HUAPONT PHARMACEUTICAL CO LTDISOTRETINOIN

DMF 345102020

HETERO DRUGS LTDISOTRETINOIN

DMF 368572022

SUN PHARMACEUTICAL INDUSTRIES LTDInactiveISOTRETINOIN USP (NON-STERILE BULK)

DMF 151692000

IPCA LABORATORIES LTDInactiveISOTRETINOIN USP

DMF 226162009

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (4)

Sort:

#001 — 10MG

AB1

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Jan 19, 2012

No patent or exclusivity listings for this strength.

#002 — 20MG

AB1

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Jan 19, 2012

#003 — 40MG

AB1

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Jan 19, 2012

#004 — 30MG

AB1

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Aug 25, 2015